South Texas Dermatopathology, PLLC Notifies Patients of Data Security Incident

SAN ANTONIO, July 19, 2019 /PRNewswire/ — South Texas Dermatopathology, PLLC has been informed by Retrieval Masters Creditors Bureau d/b/a American Medical Collection Agency (“AMCA”) of a data security incident involving the AMCA payment website. AMCA is an independent collection agency that South Texas Dermatopathology and many other entities used for debt collection.  The incident is limited to AMCA’s systems.  The security of South Texas Dermatopathology’s systems was not affected by this incident.

According to AMCA, on March 21, 2019, AMCA became aware of facts indicating there had been a data security incident. After conducting an investigation, in May of 2019, AMCA notified South Texas Dermatopathology about the incident and informed South Texas Dermatopathology that an AMCA database containing information for some South Texas Dermatopathology patients had been affected.  However, at the time of AMCA’s initial notification, AMCA did not provide South Texas Dermatopathology with enough information for South Texas Dermatopathology to identify potentially affected patients or confirm the nature of patient information potentially involved in the incident, and South Texas Dermatopathology’s investigation is on-going. Based on the information provided by AMCA, the following information belonging to South Texas Dermatopathology patients may have been affected by the incident: patient names, addresses, phone numbers, dates of birth, dates of service, balance information, credit card or banking information and treatment provider information.  AMCA has advised South Texas Dermatopathology that its patient’s social security numbers were not involved in the incident.  South Texas Dermatopathology does not provide AMCA healthcare records such as laboratory results and clinical history.

In response to the breach, AMCA sent notification letters to approximately 1,200 South Texas Dermatopathology patients informing them that their names, addresses, phone numbers, dates of birth, dates of service, balance information, credit card or banking information and treatment provider information may have been impacted. In addition, based on the investigation and the information provided by AMCA, South Texas Dermatopathology estimates that approximately another 14,900 patients may have had their names, addresses, phone numbers, dates of birth, dates of service, balance information and treatment provider information impacted by this incident.  For these patients, credit card and banking information is not affected. The impact of this incident is limited to laboratory services provided to patients in the United States whose accounts were referred for debt collection.

Individuals with questions about this incident or questions about precautionary steps they can take may call 833-300-6928 for additional information.

South Texas Dermatopathology takes the security of its patients’ information very seriously, including the security of data handled by vendors.  As a result of the investigation, South Texas Dermatopathology is no longer using AMCA for collection efforts.

The privacy and protection of patient information is a top priority.  South Texas Dermatopathology greatly appreciates the patience and loyalty of its patients as it works to respond to this incident.

View original content:http://www.prnewswire.com/news-releases/south-texas-dermatopathology-pllc-notifies-patients-of-data-security-incident-300888271.html

SOURCE South Texas Dermatopathology, PLLC

Staff

Recent Posts

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual…

2 hours ago

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or…

2 hours ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by…

2 hours ago

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading…

2 hours ago

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year…

2 hours ago

Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to May 3, 2024

MIAMI, March 29, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW)…

2 hours ago